Addex Therapeutics Ltd. (ADXN) Form 6-K — Oct 8, 2026
Addex Therapeutics announced that its spin-out Neurosterix, in which Addex holds a 20% equity interest, completed Phase 1 clinical studies of NTX-253, a muscarinic M4 positive allosteric modulator for schizophrenia. The Phase 1 program combined single and multiple ascending dose components with food-effect and CSF assessments, enrolling both healthy volunteers and stable schizophrenia patients to generate safety and pharmacokinetic data.
Key figures
- Series a financing usd
- 65000000
- Neurosterix equity stake percent
- 20
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.